FHTXHealthcare · BiotechnologyFHTX Stock Forecast: Foghorn Therapeutics, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $12 — +160.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 1 Aug 2026 — in the upper half.
FHTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (80): Sales and profits are climbing, and climbing faster than before.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership.
FHTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +160.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Mar 2026 | Wedbush | Reiterates | Outperform | $10 |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 17 Feb 2026 | Jefferies | Maintains | Buy | — |
| 18 Dec 2025 | BTIG | Initiates | Buy | — |
| 4 Dec 2025 | Stifel | Initiates | Buy | — |
| 7 Nov 2025 | Guggenheim | Initiates | Buy | — |
| 15 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 23 Apr 2025 | JMP Securities | Initiates | Market Outperform | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | B. Riley Securities | Initiates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2024 | Jefferies | Maintains | Buy | — |
| 24 Sept 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 3 Sept 2024 | Jefferies | Initiates | Buy | — |
| 19 Aug 2024 | Evercore ISI Group | Initiates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Aug 2024 | Wedbush | Reiterates | Outperform | — |
| 7 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
FHTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Foghorn Therapeutics, Inc. (FHTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.9×
- Price / sales
- 9.4×
- Price / book
- −4.1×
- EV / EBITDA
- −1.6×
Cheaper than 88% of US stocks
Cheaper than 15% of US stocks
Cheaper than 96% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- −45.1%
- Earnings growth (YoY)
- −45.1%
- Gross margin
- —
- Operating margin
- −660.3%
- Net margin
- −266.9%
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 7% of US stocks
Higher than 1% of US stocks
- Return on equity
- 68.5%
- Return on assets
- −21.0%
- Dividend yield
- —
Higher than 94% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
FHTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FHTX appears on the weeks it earns a place.
Frequently asked questions about FHTX stock
What is the FHTX stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $9 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FHTX stock a buy right now?
Of the 10 analysts covering Foghorn Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 63 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FHTX?
As at 1 Aug 2026, Foghorn Therapeutics, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (80 of 100).
Will FHTX stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +160.3% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 63 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FHTX stock forecast for 2030?
No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $14 over the next 12 months.
How has FHTX stock performed over the past year?
Foghorn Therapeutics, Inc. returned -7.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Foghorn Therapeutics, Inc. do?
Foghorn Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of precision medicine therapeutics that treat serious diseases by correcting abnormal gene expression. The company uses its proprietary Gene Traffic Control platform to systematically identify, validate, and drug targets within the chromatin regulatory system, which orchestrates how genes turn on and off in cells.
About Foghorn Therapeutics, Inc.
Foghorn Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of precision medicine therapeutics that treat serious diseases by correcting abnormal gene expression. The company uses its proprietary Gene Traffic Control platform to systematically identify, validate, and drug targets within the chromatin regulatory system, which orchestrates how genes turn on and off in cells. Foghorn is advancing nearly 10 programs across multiple cancer types, including non-small cell lung cancer, prostate cancer, breast cancer, and various lymphomas and leukemias. Its lead clinical candidate, FHD-909, is a selective SMARCA2 inhibitor in Phase 1 development for SMARCA4-mutated cancers. The company is also developing selective degrader programs targeting CBP, EP300, and ARID1B for various malignancies. Headquartered in Cambridge, Massachusetts, Foghorn maintains strategic collaborations including a partnership with Eli Lilly and Company for developing oncology therapeutics. The company addresses a significant market need, as more than half of all cancers are associated with chromatin regulatory system abnormalities.
CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com